Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

GW Pharma cannabis drug set to hit market following DEA nod

U.S.-listed shares of GW Pharmaceuticals rose 8 percent as the company’s marijuana-based treatment Epidiolex cleared the last hurdle after the Drug Enforcement Administration labeled the drug as having a low abuse potential.

Read More »

Roche’s Tecentriq, trailing rival drugs, lifts lung cancer survival

A drug cocktail with Roche’s Tecentriq added two months to small-cell lung cancer patients’ lives, according to a study, aiding the Swiss group’s bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.

Read More »

AstraZeneca buoyed as Imfinzi cuts lung cancer deaths by a third

AstraZeneca’s immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.

Read More »

Drug shortages may add $230 million to annual U.S. drug costs

Prescription drug shortages may drive up prices twice as much as they would rise with medicines in abundant supply, adding $230 million a year to U.S. drug costs, a new study estimates.

Read More »

Spark’s blindness therapy gets European panel nod

A European Medicines Agency panel recommended approval of Spark Therapeutics’ gene therapy Luxturna for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world’s costliest treatments outside the United States.

Read More »

FDA Issues Statement Reaffirming Positive Benefit-Risk Profile Of Nuplazid For Patients with Hallucinations, Delusions Associated With Parkinson’s Disease Psychosis

Acadia Pharmaceuticals Inc. announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis.

Read More »

UK rejects adult Novartis CAR-T therapy

Health authorities in England rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing Kymriah’s use in children and young people.

Read More »

Senate Overwhelmingly Passes Bill to Address Prescription Opioids

The U.S. Senate overwhelmingly supported a new bill aimed at opioid abuse and other addictive drugs.

Read More »

Post-op opioids used far more in U.S. than Hong Kong

Head and neck surgery patients in Hong Kong are far less likely to be prescribed opioids than patients undergoing similar surgeries in the U.S., new research shows.

Read More »

Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!

Subscribe

Ad Right Bottom